LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference

Rhea-AI Summary

LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Frederic Chereau will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand starting at 7:00 a.m. ET on March 30, 2022. A webcast of the presentation can be accessed in the Investors section of the company's website, with a replay available for approximately 30 days. LogicBio focuses on genome editing and gene delivery for rare diseases, utilizing its GeneRide™ and sAAVy™ platforms.

LEXINGTON, Mass., March 23, 2022 /PRNewswire/ -- LogicBio^® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand beginning at 7:00 a.m. ET on March 30, 2022.

A webcast of the presentation will be made available on the Investors section of the Company's website at https://investor.logicbio.com. The webcast replay will be available for approximately 30 days.

About LogicBio® Therapeutics 

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

Investor Contacts: 
Stephen Jasper
Gilmartin Group
858-525-2047
stephen@gilmartinir.com 

Media Contacts:
Adam Daley
Berry & Company Public Relations
W:212-253-8881
C: 614-580-2048
adaley@berrypr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-hc-wainwright-gene-therapy-and-gene-editing-conference-301509368.html

SOURCE LogicBio Therapeutics

FAQ

When will LogicBio present at the H.C. Wainwright Conference?

LogicBio will present on March 30, 2022, starting at 7:00 a.m. ET.

Where can I watch the LogicBio conference presentation?

The presentation will be available on the Investors section of LogicBio's website.

What are the platforms developed by LogicBio Therapeutics?

LogicBio has developed GeneRide™ for gene insertion and sAAVy™ for optimized gene delivery.

What is the focus of LogicBio Therapeutics?

LogicBio focuses on genetic medicine for rare and serious diseases.

How long will the webcast of LogicBio's presentation be available?

The webcast replay will be available for approximately 30 days.